Levetiracetam Solution
Product Images NDC 55154-5782

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 55154-5782). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cardinal Health 107, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

033f39c3 8011 47c4 A1d7 866ff2d83801 00

Label for Levetiracetam oral solution USP, 500 mg per 5 mL, supplied in 5 x 5 mL unit dose cups. The label includes storage instructions, dosage reference, and warnings indicating it is intended for institutional in-patient dispensing only. It is distributed by Cardinal Health 107, LLC and manufactured by Pharmaceutical Associates, Inc.*

FDA Label Image

Chemical Structure (Levetiracetam 01)

Chemical structure of levetiracetam, showing its characteristic molecular arrangement including a pyrrolidone ring and side chains labeled with atomic groups such as CH3, CH2, and CONH2.*

FDA Label Image

Figure 1 (Levetiracetam 02)

A bar graph comparing the percentage of patients among three groups: placebo, levetiracetam 1000 mg/day, and levetiracetam 3000 mg/day. The percentages shown are 7.4% for placebo, 37.1% for 1000 mg/day, and 39.6% for 3000 mg/day.*

FDA Label Image

Figure 2 (Levetiracetam 03)

A bar chart comparing the percentage of patients across three groups: Placebo, Levetiracetam 1000 mg/day, and Levetiracetam 2000 mg/day. The y-axis represents the percentage of patients, with values ranging from 0% to 45%. The bars show 6.3% for Placebo, 20.8% for Levetiracetam 1000 mg/day, and 35.2% for Levetiracetam 2000 mg/day.*

FDA Label Image

Figure 3 (Levetiracetam 04)

A bar graph comparing the percentage of patients between two groups: one receiving a placebo (N=104) and the other receiving Levetiracetam 3000 mg/day (N=180). The Levetiracetam group shows a higher percentage of patients at 39.4% versus 14.4% for the placebo group.*

FDA Label Image

Figure 4 (Levetiracetam 05)

A bar graph showing the percentage of patients responding to treatment with Levetiracetam oral solution 500 mg/5mL compared to placebo. The graph presents two bars labeled Placebo and Levetiracetam, with respective patient sample sizes of 97 and 101. The Levetiracetam group shows a higher percentage response at 44.6% versus 19.6% for placebo.*

FDA Label Image

Figure 5 (Levetiracetam 06)

A bar chart comparing the percentage of patients between Placebo and Levetiracetam groups. The Levetiracetam group shows a higher percentage (43.1%) compared to the Placebo group (19.6%), with a note indicating statistical significance versus placebo.*

FDA Label Image

Figure 6 (Levetiracetam 07)

Bar chart comparing the percentage of patients between placebo and levetiracetam groups. The y-axis represents percent of patients from 0% to 100%. The placebo group (N=84) shows 45.2%, while the levetiracetam group (N=79) shows 72.2%.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.